Cargando…

Use of Pralsetinib as Neoadjuvant Therapy for Non-Small Cell Lung Cancer Patient With RET Rearrangement

RET rearrangements are rare, and occur in 1%-2% of all non-small cell lung cancer (NSCLC) patients. Pralsetinib has a significant anti-tumor effect in patients with advanced NSCLC and a RET rearrangement. Previous studies have confirmed the efficiency of neoadjuvant target therapy for NSCLC. Herein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Ning, Li, Tong, Liang, Maoli, Ren, Fan, Ni, Hong, Liu, Wei, Shi, Tao, Xu, Dongbo, Chen, Qiusong, Yu, Haonan, Song, Zuoqing, Zu, Lingling, Li, Shuo, Xu, Song
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866561/ https://www.ncbi.nlm.nih.gov/pubmed/35223529 http://dx.doi.org/10.3389/fonc.2022.848779

Ejemplares similares

RET rearrangement-positive pancreatic cancer has remarkable response to pralsetinib: a case report
por: Zhang, Tongyi, et al.
Publicado: (2023)

Expanded Access Program Pralsetinib in Advanced Non–Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement
por: Jeon, Youngkyung, et al.
Publicado: (2023)

Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with RET-fusion positive NSCLC
por: An, Li, et al.
Publicado: (2022)

Case report: Dramatic response to pralsetinib in an elderly patient with advanced RET-fusion positive papillary thyroid carcinoma
por: Nannini, Margherita, et al.
Publicado: (2022)

Case Report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Corrigendum: Case report: A novel intergenic MIR4299/MIR8070-RET fusion with RET amplification and clinical response to pralsetinib in a lung adenocarcinoma patient
por: Wang, Sha-Sha, et al.
Publicado: (2022)

Pralsetinib-associated pneumonia in RET fusion-positive non-small cell lung cancer
por: Gao, Ming, et al.
Publicado: (2023)

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report
por: d'Arienzo, Paolo D., et al.
Publicado: (2023)

Use of savolitinib as neoadjuvant therapy for non–small cell lung cancer patient with MET exon 14 skipping alterations: A case report
por: Zhang, Yu, et al.
Publicado: (2022)

Pralsetinib treatment for multiple RET fusions in lung adenocarcinoma: a case report
por: Cao, Xiangming, et al.
Publicado: (2022)

Response to Pralsetinib in Multi-Drug-Resistant Breast Cancer With CCDC6-RET Mutation
por: Zhao, Jing, et al.
Publicado: (2023)

Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report
por: Zhao, Shikang, et al.
Publicado: (2021)

Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations
por: Subbiah, V., et al.
Publicado: (2020)

Partial response to pralsetinib in an advanced pulmonary sarcomatoid carcinoma patient harboring a KIF5B-RET rearrangement: a case report
por: Wu, Ying, et al.
Publicado: (2022)

Pralsetinib for the treatment of a RET-positive advanced non-small-cell lung cancer patient harboring both ANK-RET and CCDC6-RET fusions with coronary heart disease: a case report
por: Meng, Yan, et al.
Publicado: (2022)

The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib
por: Shen, Tao, et al.
Publicado: (2021)

Significant response to pralsetinib in a medullary thyroid cancer harboring double RET variants of unknown significance
por: Hescot, Ségolène, et al.
Publicado: (2022)

First-line versus second-line use of pralsetinib in treatment of rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis
por: Liu, Wenjie, et al.
Publicado: (2023)

Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report
por: Gu, Linping, et al.
Publicado: (2022)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
por: Zhao, Zichen, et al.
Publicado: (2022)

Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation
por: Zhang, Bo, et al.
Publicado: (2022)

Frequent Genetic Alterations and Their Clinical Significance in Patients With Thymic Epithelial Tumors
por: Xu, Song, et al.
Publicado: (2021)

Neoadjuvant camrelizumab and chemotherapy in patients with resectable stage IIIA squamous non-small-cell lung cancer: Clinical experience of three cases
por: Li, Xin, et al.
Publicado: (2022)

Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
por: Subbiah, Vivek, et al.
Publicado: (2022)

Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2023)

RET signaling pathway and RET inhibitors in human cancer
por: Regua, Angelina T., et al.
Publicado: (2022)

PD-1/PD-L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review)
por: Tang, Quanying, et al.
Publicado: (2023)

Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
por: Gouda, Mohamed A., et al.
Publicado: (2023)

Clinical development of RET inhibitors in RET-rearranged non-small cell lung cancer: Update
por: Mendoza, Luis
Publicado: (2018)

The Epidemiology of Ground Glass Opacity Lung Adenocarcinoma: A Network-Based Cumulative Meta-Analysis
por: Li, Xiongfei, et al.
Publicado: (2020)

Immunophenotype and Response to Immunotherapy of RET-Rearranged Lung Cancers
por: Offin, Michael, et al.
Publicado: (2019)

A Case of Simultaneously Diagnosed Lung Adenocarcinoma and Endobronchial Inflammatory Myofibroblastic Tumor with Two Distinct Types of ALK Translocation
por: Zhao, Shikang, et al.
Publicado: (2021)

RET rearrangements are relevant to histopathologic subtypes and clinicopathological features in Thai papillary thyroid carcinoma patients
por: Khonrak, Thitima, et al.
Publicado: (2023)

Lobe-Specific Analysis of Sublobar Lung Resection for NSCLC Patients with Tumors ≤ 2 cm
por: Lei, Xi, et al.
Publicado: (2022)

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer
por: Urbanska, Edyta M., et al.
Publicado: (2022)

Targeted therapy of RET fusion-positive non-small cell lung cancer
por: Shen, Zixiong, et al.
Publicado: (2022)

A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring KIF5B-RET Fusion Responds to First-Line Pralsetinib Treatment: A Case Report
por: Qin, Hao, et al.
Publicado: (2023)

The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research
por: Meng, Yan, et al.
Publicado: (2022)

Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage RET fusion-positive non-small cell lung cancer
por: Goldman, Jonathan W., et al.
Publicado: (2023)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_q52viq3ft4voq8ns2hrh82o8lg